Valeant CEO Explains Why The Company Is Acquiring Salix For $10.1 Billion Cash Instead Of An Equity Offering

By: via Benzinga
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced earlier Monday that it will be acquiring Salix Pharmaceuticals, Ltd. (NASDAQ: ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.